Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry
Our findings underscore two critical areas for enhancing biosimilar infliximab usage: increasing switching among prevalent users and increasing uptake among Medicare beneficiaries initiating treatment. Significant variation in uptake across practices also suggests that local switching policies are likely key drivers of uptake.
Authors
- Chien‐Wen Tseng (ORCID: https://orcid.org/0000-0001-7162-2550)
- Jinoos Yazdany (ORCID: https://orcid.org/0000-0002-3508-4094)
- Gabriela Schmajuk (ORCID: https://orcid.org/0000-0003-2687-5043)
- Stephen Shiboski (ORCID: https://orcid.org/0000-0002-9257-2609)
- Eric T. Roberts (ORCID: https://orcid.org/0009-0005-8435-8994)
- Jing Li (ORCID: https://orcid.org/0000-0001-7986-0078)
- Nick Bansback
Institutions
- University of Hawaiʻi at Mānoa (US)
- San Francisco General Hospital (US)
- San Francisco VA Medical Center (US)
- University of British Columbia (CA)
- University of California, San Francisco (US)
Publication Details
- Journal
- Health Services Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/1475-6773.14410
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Agency for Healthcare Research and Quality
- National Institute of Arthritis and Musculoskeletal and Skin Diseases